Category Medicine and Healthcare
Press Release
Wellgistics Health Launches Capital Access Program for 6,500+ Pharmacies and Supply Chain Partners, Unlocking up to $1M in Working Capital
In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience. Read More
Press Release
Dr. Sean Doherty Recognized Among "America’s Best Plastic Surgeons" for the 3rd Year in a Row
Recognition in breast augmentation and liposuction highlights Dr. Doherty's expertise in two of the most requested cosmetic procedures, underscoring his reputation for natural outcomes and patient-centered care. Read More
Press Release
Medicus Pharma Ltd. To Present at Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer D-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity Read More
Press Release
Congress Trying to Limit Marijuana Rescheduling, but DEA Can Still Act Now
Administrator Cole, you can fight illicit drugs and build a lawful, GMP-grade cannabinoid supply chain that shrinks the black market through science. Approve qualified marijuana manufacturers and research investigators now. Patients are waiting. Read More
Press Release
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
Full year fiscal 2025 net revenue of $66.4 million Full year fiscal 2025 net loss of $13.6 million Full year fiscal 2025 adjusted EBITDA1 of $9.2 million $31.0 million cash balance at June 30, 2025 Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD Company to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time Read More
Press Release
CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities
Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies Read More
Press Release
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains Read More
Press Release
Most RPM & CCM Programs Create More Headaches Than Health
Connectivity failures, OS updates, and frustrated patients shouldn't be your problem. Silent devices, outsourced call centers, and disengaged patients create hidden risks and liability. Addison Care delivers fully integrated Virtual Care - engaging patients, protecting providers, and maximizing Medicare value. Read More
Press Release
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with ketamine. Read More
Press Release
IBYC Selects Makeer Intelligence as Exclusive Hardware Partner and Launches Canada-Focused Pilot for Multilingual Asian Seniors
IBYC, based in Richmond, BC, is a next-generation digital health company developing AI-powered telemedicine and wearable solutions to improve access to care anytime, anywhere. The company focuses on mobile health monitoring, senior and multilingual populations, and caregiver support through secure, real-time biometric data analysis and AI insights. Founded by entrepreneurs with 20+ years of China-Canada experience, IBYC integrates technology, compliance, and cross-border resources to build scalable, culturally competent healthcare platforms. Addressing care gaps as 700,000 BC residents lack family doctors and seniors are set to grow 68% over the next two decades Read More
Press Release
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth. Read More
Press Release
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity Read More
Press Release
DistillerSR Launches First-of-Its-Kind Agentic AI Capabilities to Eliminate Evidence Silos and Accelerate Time to Market
New Capabilities Place Peer-reviewed Literature Review Evidence at the Fingertips of Research and Commercial Teams to Align Decision-making and Improve Productivity Read More
Press Release
Keensight Capital Acquires Majority Stake in Isto Biologics, a Leading Orthobiologics Player, from Thompson Street Capital Partners
Keensight Capital ("Keensight"), one of the leading private equity managers dedicated to pan-European Growth Buyout [1] investments, today announced it has agreed to acquire a majority stake in Isto Biologics ("Isto") from Thompson Street Capital Partners ("TSCP"). TSCP will retain a minority stake, alongside Isto Biologics' management team. Read More
Press Release
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_stallion/ The influencers have hundreds of thousands of followers across social platforms BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world Sublingual delivery of 50mg of caffeine to the user in less than two minutes BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's E-commerce website Read More
Press Release
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study Preclinical proof-of-concept data on PN-881, a first-in-class oral peptide targeting the IL-17 pathway, and part of Protagonist's fully owned development pipeline, including the highly potent and selective binding of IL-17A and IL-17F Read More
Press Release
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - Read More
Press Release
As Fall Sports Season Begins, ZetrOZ Systems' SAM Technology Helps Athletes Prevent Re-Injury
Sustained acoustic medicine helps athletes bridge that critical gap between recovery and performance by providing an advanced, non-invasive therapy proven to accelerate healing and reduce pain Read More
Press Release
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ BOMB™ pre-workout: 50mg caffeine for energy and focus. Boosts performance potential. Stick packs: Convenient, no water needed. Precise caffeine dose Global Market Insights: Pre-Workout Supplements Market Size in 2024: $19.6 billion Projected Market Size by 2030: $27.9 billion Compound Annual Growth Rate (CAGR): 5.9% Read More
Press Release
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment Read More
Press Release
CBD Life Sciences Inc. (CBDL) Huge Momentum Following NECANN New Jersey 2025
The U.S. marijuana dispensary market is projected to generate over $31.8 billion annually by 2025, creating multi-million-dollar opportunities for CBDL through dispensary partnerships and large-scale beverage distribution in sports stadiums nationwide. Read More
Press Release
Longwood Healthcare Leaders to Host Boston CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders
Leading life science executives, government officials, academic leaders, and investors gather for two day off-the-record networking and discussion forum Read More
Press Release